{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:25:34Z","timestamp":1793834734926,"version":"4.6.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"crossref","award":["Y-pierrefabre202101-0045"],"award-info":[{"award-number":["Y-pierrefabre202101-0045"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100032579","name":"Beijing Medical Award Foundation","doi-asserted-by":"publisher","award":["YXJL-2022-0620-0288"],"award-info":[{"award-number":["YXJL-2022-0620-0288"]}],"id":[{"id":"10.13039\/100032579","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors have shown encouraging clinical efficacy in breast cancer, primarily by modulating the tumor microenvironment (TME). However, achieving durable clinical responses remains a major challenge. Although the deubiquitinating enzyme 26S proteasome non-ATPase regulatory subunit 14 (PSMD14) is known to exert oncogenic functions in various cancers, its potential role in regulating tumor immune evasion remains unclear. This study investigates how PSMD14 regulates PD-L1 and reshapes the TME, with the goal of clarifying its impact on immune regulation in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PSMD14 expression and its prognostic significance in breast cancer were analyzed using public databases and clinical samples. The correlation between PSMD14 and PD-L1 was validated by immunohistochemistry (IHC), western blot, and flow cytometry. The mechanism by which PSMD14 stabilizes PD-L1 through deubiquitination and their interaction was investigated using cycloheximide chase assays, co-immunoprecipitation (Co-IP), and ubiquitination assays. The impact of PSMD14 on the TME and its influence on immunotherapy efficacy were evaluated using T cell cytotoxicity assays, syngeneic mouse models, and flow cytometry analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PSMD14 was highly expressed in breast cancer and correlated with poor patient prognosis. Mechanistically, PSMD14 stabilized PD-L1 by interacting with its intracellular domain and removing its K48-linked polyubiquitin chains, thereby inhibiting proteasomal degradation. Inhibition of PSMD14 enhanced antigen presentation and CD8\u207a T cell activation, reduced the accumulation of regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), and altered macrophage polarization. These changes collectively improved the response to immunotherapy in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study identifies PSMD14 as a critical regulator of immune responses in breast cancer. Targeting PSMD14 enhances the effectiveness of immunotherapy by promoting PD-L1 degradation and remodeling the TME, offering a potential strategy to improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03710-w","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:06:53Z","timestamp":1776136013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Targeting PSMD14 enhances immunotherapy efficacy by promoting PD-L1 degradation and reshaping the tumor microenvironment in breast cancer"],"prefix":"10.1186","volume":"45","author":[{"given":"Shichao","family":"Wen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"1","key":"3710_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Xu L, Luo S, Wu K. Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021;14(1):10.","journal-title":"J Hematol Oncol"},{"key":"3710_CR2","doi-asserted-by":"crossref","unstructured":"Kim SB, Hwang S, Cha JY, Lee HJ. Programmed Death Ligand 1 Regulatory Crosstalk with Ubiquitination and Deubiquitination: Implications in Cancer Immunotherapy. Int J Mol Sci. 2024;25(5):2939.","DOI":"10.3390\/ijms25052939"},{"issue":"1","key":"3710_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","volume":"15","author":"M Wu","year":"2022","unstructured":"Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"3710_CR4","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.3739","volume":"20","author":"D Popovic","year":"2014","unstructured":"Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat Med. 2014;20(11):1242\u201353.","journal-title":"Nat Med"},{"key":"3710_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1146\/annurev-biochem-060310-170328","volume":"81","author":"D Komander","year":"2012","unstructured":"Komander D, Rape M. The ubiquitin code. Annu Rev Biochem. 2012;81:203\u201329.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"3710_CR6","doi-asserted-by":"publisher","first-page":"e1204","DOI":"10.1002\/ctm2.1204","volume":"13","author":"C Sampson","year":"2023","unstructured":"Sampson C, Wang Q, Otkur W, et al. The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. Clin Transl Med. 2023;13(3):e1204.","journal-title":"Clin Transl Med"},{"issue":"2","key":"3710_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41418-020-00708-5","volume":"28","author":"PE Cockram","year":"2021","unstructured":"Cockram PE, Kist M, Prakash S, Chen SH, Wertz IE, Vucic D. Ubiquitination in the regulation of inflammatory cell death and cancer. Cell Death Differ. 2021;28(2):591\u2013605.","journal-title":"Cell Death Differ"},{"issue":"1","key":"3710_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","volume":"82","author":"SM Lange","year":"2022","unstructured":"Lange SM, Armstrong LA, Kulathu Y, Deubiquitinases. From mechanisms to their inhibition by small molecules. Mol Cell. 2022;82(1):15\u201329.","journal-title":"Mol Cell"},{"key":"3710_CR9","doi-asserted-by":"crossref","unstructured":"Li Y, Reverter D. Molecular Mechanisms of DUBs Regulation in Signaling and Disease. Int J Mol Sci. 2021;22(3):986.","DOI":"10.3390\/ijms22030986"},{"key":"3710_CR10","doi-asserted-by":"publisher","first-page":"108865","DOI":"10.1016\/j.pharmthera.2025.108865","volume":"271","author":"C Torrado","year":"2025","unstructured":"Torrado C, Ashton NW, D\u2019Andrea AD, Yap TA. USP1 inhibition: A journey from target discovery to clinical translation. Pharmacol Ther. 2025;271:108865.","journal-title":"Pharmacol Ther"},{"issue":"10","key":"3710_CR11","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1038\/s41418-023-01219-9","volume":"30","author":"Z Kuang","year":"2023","unstructured":"Kuang Z, Liu X, Zhang N, et al. USP2 promotes tumor immune evasion via deubiquitination and stabilization of PD-L1. Cell Death Differ. 2023;30(10):2249\u201364.","journal-title":"Cell Death Differ"},{"key":"3710_CR12","doi-asserted-by":"crossref","unstructured":"He L, Yu C, Qin S et al. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity. Mol Cell. 2023;83(22):4000-16.e6.","DOI":"10.1016\/j.molcel.2023.10.019"},{"issue":"12","key":"3710_CR13","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.7150\/thno.46109","volume":"11","author":"C Jing","year":"2021","unstructured":"Jing C, Li X, Zhou M, et al. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation. Theranostics. 2021;11(12):5847\u201362.","journal-title":"Theranostics"},{"key":"3710_CR14","doi-asserted-by":"crossref","unstructured":"Lu RS, Ren LK, Fei XB et al. PSMD14-Mediated LDHA Deubiquitination Upregulates ACLY Expression via H3K18 Lactylation to Promote Lipid Synthesis and Pancreatic Cancer Progression. Adv Sci (Weinh). 2025:e05762.","DOI":"10.1002\/advs.202505762"},{"issue":"19","key":"3710_CR15","doi-asserted-by":"publisher","first-page":"eadr3173","DOI":"10.1126\/sciadv.adr3173","volume":"11","author":"Y Yu","year":"2025","unstructured":"Yu Y, Hu J, Wang W, et al. Targeting PSMD14 combined with arachidonic acid induces synthetic lethality via FADS1 m(6)A modification in triple-negative breast cancer. Sci Adv. 2025;11(19):eadr3173.","journal-title":"Sci Adv"},{"issue":"4","key":"3710_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41388-023-02905-1","volume":"43","author":"P Yang","year":"2024","unstructured":"Yang P, Yang X, Wang D, et al. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ER\u03b1. Oncogene. 2024;43(4):248\u201364.","journal-title":"Oncogene"},{"issue":"8","key":"3710_CR17","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1111\/cas.70064","volume":"116","author":"M Zhou","year":"2025","unstructured":"Zhou M, Li X, Wang W, Wu J, Tan J. PSMD14\/E2F1 Axis-Mediated CENPF Promotes the Metastasis of Triple-Negative Breast Cancer Through Inhibiting Ferroptosis. Cancer Sci. 2025;116(8):2281\u201395.","journal-title":"Cancer Sci"},{"issue":"3","key":"3710_CR18","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143\u201352.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3710_CR19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","volume":"28","author":"D Zhu","year":"2021","unstructured":"Zhu D, Xu R, Huang X, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021;28(6):1773\u201389.","journal-title":"Cell Death Differ"},{"issue":"14","key":"3710_CR20","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1158\/1078-0432.CCR-16-3215","volume":"23","author":"S Jiao","year":"2017","unstructured":"Jiao S, Xia W, Yamaguchi H, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017;23(14):3711\u201320.","journal-title":"Clin Cancer Res"},{"key":"3710_CR21","doi-asserted-by":"publisher","first-page":"107668","DOI":"10.1016\/j.phrs.2025.107668","volume":"214","author":"F Shi","year":"2025","unstructured":"Shi F, Li GJ, Liu Y, et al. USP19 deficiency enhances T-cell-mediated antitumor immunity by promoting PD-L1 degradation in colorectal cancer. Pharmacol Res. 2025;214:107668.","journal-title":"Pharmacol Res"},{"issue":"Pt 1","key":"3710_CR22","doi-asserted-by":"publisher","first-page":"147275","DOI":"10.1016\/j.ijbiomac.2025.147275","volume":"327","author":"Y Liu","year":"2025","unstructured":"Liu Y, Wen S, Wang W, et al. PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K\/AKT\/mTOR pathway. Int J Biol Macromol. 2025;327(Pt 1):147275.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"3710_CR23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms Controlling PD-L1 Expression in Cancer. Mol Cell. 2019;76(3):359\u201370.","journal-title":"Mol Cell"},{"key":"3710_CR24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2019.10.025","volume":"469","author":"J Lv","year":"2020","unstructured":"Lv J, Zhang S, Wu H, et al. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2. Cancer Lett. 2020;469:22\u201334.","journal-title":"Cancer Lett"},{"key":"3710_CR25","doi-asserted-by":"crossref","unstructured":"Lu J, Wu H, Zhan P, et al. PSMD14-mediated deubiquitination of CARM1 facilitates the proliferation and metastasis of hepatocellular carcinoma by inducing the transcriptional activation of FERMT1. Cell Death Dis. 2025;16(1):141.","DOI":"10.1038\/s41419-025-07416-3"},{"key":"3710_CR26","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"3710_CR27","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1084\/jem.20051776","volume":"203","author":"ME Keir","year":"2006","unstructured":"Keir ME, Liang SC, Guleria I, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883\u201395.","journal-title":"J Exp Med"},{"issue":"4","key":"3710_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.eururo.2015.11.029","volume":"70","author":"Y Messai","year":"2016","unstructured":"Messai Y, Gad S, Noman MZ, et al. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status. Eur Urol. 2016;70(4):623\u201332.","journal-title":"Eur Urol"},{"issue":"1","key":"3710_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-023-01883-y","volume":"22","author":"Z Miao","year":"2023","unstructured":"Miao Z, Li J, Wang Y, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375\/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer. 2023;22(1):205.","journal-title":"Mol Cancer"},{"issue":"2","key":"3710_CR30","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41418-022-01102-z","volume":"30","author":"H Yang","year":"2023","unstructured":"Yang H, Zhang X, Lao M, et al. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. Cell Death Differ. 2023;30(2):560\u201375.","journal-title":"Cell Death Differ"},{"issue":"3","key":"3710_CR31","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.apsb.2020.11.005","volume":"11","author":"Z Wang","year":"2021","unstructured":"Wang Z, Kang W, Li O, et al. Abrogation of USP7 is an alternative strategy to downregulate PD-L1 and sensitize gastric cancer cells to T cells killing. Acta Pharm Sin B. 2021;11(3):694\u2013707.","journal-title":"Acta Pharm Sin B"},{"key":"3710_CR32","doi-asserted-by":"crossref","unstructured":"Krshnan L, van de Weijer ML, Carvalho P. Endoplasmic Reticulum-Associated Protein Degradation. Cold Spring Harb Perspect Biol. 2022;14(12):a041247.","DOI":"10.1101\/cshperspect.a041247"},{"issue":"6","key":"3710_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, et al. Deubiquitination and Stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925\u201339.","journal-title":"Cancer Cell"},{"key":"3710_CR34","doi-asserted-by":"crossref","unstructured":"Yu ZZ, Liu YY, Zhu W et al. ANXA1-derived peptide for targeting PD-L1 degradation inhibits tumor immune evasion in multiple cancers. J Immunother Cancer. 2023;11(3):e006345.","DOI":"10.1136\/jitc-2022-006345"},{"key":"3710_CR35","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.semcdb.2021.12.009","volume":"132","author":"A Mart\u00ednez-F\u00e9rriz","year":"2022","unstructured":"Mart\u00ednez-F\u00e9rriz A, Ferrando A, Fathinajafabadi A, Farr\u00e0s R. Ubiquitin-mediated mechanisms of translational control. Semin Cell Dev Biol. 2022;132:146\u201354.","journal-title":"Semin Cell Dev Biol"},{"issue":"10","key":"3710_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41419-024-07137-z","volume":"15","author":"T Xia","year":"2024","unstructured":"Xia T, Meng L, Xu G, Sun H, Chen H. TRIM33 promotes glycolysis through regulating P53 K48-linked ubiquitination to promote esophageal squamous cell carcinoma growth. Cell Death Dis. 2024;15(10):740.","journal-title":"Cell Death Dis"},{"issue":"1","key":"3710_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s11658-020-00245-6","volume":"26","author":"M Tracz","year":"2021","unstructured":"Tracz M, Bialek W. Beyond K48 and K63: non-canonical protein ubiquitination. Cell Mol Biol Lett. 2021;26(1):1.","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"3710_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"3710_CR39","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","volume":"12","author":"D Hammerl","year":"2021","unstructured":"Hammerl D, Martens JWM, Timmermans M, et al. Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. Nat Commun. 2021;12(1):5668.","journal-title":"Nat Commun"},{"key":"3710_CR40","doi-asserted-by":"crossref","unstructured":"Minnar CM, Chariou PL, Horn LA et al. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer. 2022;10(6):e004561.","DOI":"10.1136\/jitc-2022-004561"},{"key":"3710_CR41","doi-asserted-by":"crossref","unstructured":"Zhang Y, Zeng L, Wang M et al. RIG-I promotes immune evasion of colon cancer by modulating PD-L1 ubiquitination. J Immunother Cancer. 2023;11(9):e007313.","DOI":"10.1136\/jitc-2023-007313"},{"issue":"1","key":"3710_CR42","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1038\/s41467-022-29401-6","volume":"13","author":"W Xiong","year":"2022","unstructured":"Xiong W, Gao X, Zhang T, et al. USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. Nat Commun. 2022;13(1):1700.","journal-title":"Nat Commun"},{"key":"3710_CR43","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1146\/annurev-immunol-032414-112334","volume":"33","author":"J Rossjohn","year":"2015","unstructured":"Rossjohn J, Gras S, Miles JJ, Turner SJ, Godfrey DI, McCluskey J. T cell antigen receptor recognition of antigen-presenting molecules. Annu Rev Immunol. 2015;33:169\u2013200.","journal-title":"Annu Rev Immunol"},{"key":"3710_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1146\/annurev.immunol.23.021704.115658","volume":"24","author":"MG Rudolph","year":"2006","unstructured":"Rudolph MG, Stanfield RL, Wilson IA. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol. 2006;24:419\u201366.","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"3710_CR45","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas G, Konopacki C, Wu K, et al. Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity. 2016;45(5):1122\u201334.","journal-title":"Immunity"},{"issue":"3","key":"3710_CR46","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","volume":"41","author":"C Tay","year":"2023","unstructured":"Tay C, Tanaka A, Sakaguchi S. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Cancer Cell. 2023;41(3):450\u201365.","journal-title":"Cancer Cell"},{"issue":"1","key":"3710_CR47","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24(1):5.","journal-title":"Mol Cancer"},{"issue":"1","key":"3710_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41392-023-01337-3","volume":"8","author":"R Zhang","year":"2023","unstructured":"Zhang R, Dong M, Tu J, et al. PMN-MDSCs modulated by CCL20 from cancer cells promoted breast cancer cell stemness through CXCL2-CXCR2 pathway. Signal Transduct Target Ther. 2023;8(1):97.","journal-title":"Signal Transduct Target Ther"},{"issue":"47","key":"3710_CR49","doi-asserted-by":"publisher","first-page":"eabo4116","DOI":"10.1126\/sciadv.abo4116","volume":"8","author":"E Montauti","year":"2022","unstructured":"Montauti E, Weinberg SE, Chu P, et al. A deubiquitination module essential for T(reg) fitness in the tumor microenvironment. Sci Adv. 2022;8(47):eabo4116.","journal-title":"Sci Adv"},{"issue":"20","key":"3710_CR50","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-20-3909","volume":"81","author":"DK Ahirwar","year":"2021","unstructured":"Ahirwar DK, Charan M, Mishra S, et al. Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages. Cancer Res. 2021;81(20):5255\u201367.","journal-title":"Cancer Res"},{"issue":"4","key":"3710_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1182\/blood.2019003990","volume":"136","author":"K Wu","year":"2020","unstructured":"Wu K, Yuan Y, Yu H, et al. The gut microbial metabolite trimethylamine N-oxide aggravates GVHD by inducing M1 macrophage polarization in mice. Blood. 2020;136(4):501\u201315.","journal-title":"Blood"},{"key":"3710_CR52","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12885-015-1546-9","volume":"15","author":"M Genin","year":"2015","unstructured":"Genin M, Clement F, Fattaccioli A, Raes M, Michiels C. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC Cancer. 2015;15:577.","journal-title":"BMC Cancer"},{"key":"3710_CR53","doi-asserted-by":"publisher","first-page":"115414","DOI":"10.1016\/j.biopha.2023.115414","volume":"166","author":"L Shang","year":"2023","unstructured":"Shang L, Zhong Y, Yao Y, et al. Subverted macrophages in the triple-negative breast cancer ecosystem. Biomed Pharmacother. 2023;166:115414.","journal-title":"Biomed Pharmacother"},{"key":"3710_CR54","doi-asserted-by":"publisher","first-page":"104103","DOI":"10.1016\/j.critrevonc.2023.104103","volume":"190","author":"N Fusco","year":"2023","unstructured":"Fusco N, Ivanova M, Frascarelli C, et al. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey. Crit Rev Oncol Hematol. 2023;190:104103.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"3710_CR55","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020;382(9):810\u201321.","journal-title":"N Engl J Med"},{"issue":"18","key":"3710_CR56","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-24-3748","volume":"85","author":"J Zhang","year":"2025","unstructured":"Zhang J, Chen W, Zhang C, et al. Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion. Cancer Res. 2025;85(18):3435\u201353.","journal-title":"Cancer Res"},{"issue":"40","key":"3710_CR57","doi-asserted-by":"publisher","first-page":"5631","DOI":"10.1038\/onc.2017.172","volume":"36","author":"Y Song","year":"2017","unstructured":"Song Y, Li S, Ray A, et al. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Oncogene. 2017;36(40):5631\u20138.","journal-title":"Oncogene"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03710-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03710-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:58:33Z","timestamp":1781647113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03710-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3710"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03710-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research ethics committee of the Harbin Medical University Cancer Hospital granted approval for the use of human subjects, and informed consent was obtained from each participant. All animal experiments were performed in accordance with the Harbin Medical University Animal Ethics Committee (NO. KY2023-02 and NO. KY2022-53).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}